Scarica l'app Stockscreener
5.59
3.45%
-0.20
Precedente Chiudi:
$5.79
Aprire:
$5.85
Volume 24 ore:
1.20M
Relative Volume:
1.48
Capitalizzazione di mercato:
$175.27M
Reddito:
$19.09M
Utile/perdita netta:
$-82.13M
Rapporto P/E:
-1.9946
EPS:
-2.8026
Flusso di cassa netto:
$-70.00M
1 W Prestazione:
-5.09%
1M Prestazione:
-15.05%
6M Prestazione:
-62.41%
1 anno Prestazione:
-83.68%
Intervallo 1D:
$5.3414
$5.86
Intervallo di 1 settimana:
$5.23
$6.21
Portata 52W:
$5.23
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Nome
Lenz Therapeutics Inc
Settore
Industria
Telefono
858-925-7000
Indirizzo
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
5.59 | 175.27M | 19.09M | -82.13M | -70.00M | -2.8026 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2025-03-18 | Iniziato | TD Cowen | Buy |
| 2024-09-27 | Iniziato | Raymond James | Outperform |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-04-10 | Iniziato | Citigroup | Buy |
| 2024-03-27 | Iniziato | Piper Sandler | Overweight |
| 2023-02-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-01-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-14 | Iniziato | BTIG Research | Buy |
| 2022-03-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Iniziato | Morgan Stanley | Overweight |
| 2021-07-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie
LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions - Yahoo Finance
Piper Sandler Maintains LENZ Therapeutics(LENZ.US) With Hold Rating, Maintains Target Price $12 - Moomoo
H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $38 - Moomoo
LENZ Therapeutics Launches VIZZ Telehealth Prescribing Option for the Treatment of Presbyopia - VisionMonday.com
H.C. Wainwright reiterates Buy on LENZ Therapeutics stock on telehealth launch - Investing.com
LENZ Reiterates by HC Wainwright & Co. -- Price Target Maintained at $38 - GuruFocus
LENZ Therapeutics Inc (LENZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LENZ Therapeutics, Inc. Launches New Telehealth Prescribing Option for VIZZ for the Treatment of Presbyopia - marketscreener.com
William Blair Maintains LENZ Therapeutics(LENZ.US) With Buy Rating - Moomoo
LENZ Therapeutics Launches Telehealth Access for VIZZ Alongside National TV Campaign - Quiver Quantitative
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ - LENZ Therapeutics
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia - Yahoo Finance
LENZLENZ Therapeutics Inc Options - Finviz
Director departure and audit committee change at LENZ Therapeutics (NASDAQ: LENZ) - Stock Titan
Price to book forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
Price to sales forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
Enterprise value to EBIT forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
Enterprise value to revenue forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
Price to earnings forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
Enterprise value to EBITDA forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to Russell Microcap Value Benchmark Index - marketscreener.com
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) added to Russell 2000 Value Benchmark - marketscreener.com
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) dropped from Russell 3000 Growth Benchmark - marketscreener.com
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) dropped from Russell 3000E Growth Benchmark - marketscreener.com
LENZ Therapeutics Surges 5.6%: Key Levels to WatchMomentum Stock Picks - dars.gov.et
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Millennium Group reports 1.60M-share (5.1%) LENZ stake (LENZ) - Stock Titan
LENZ Therapeutics, Inc. Actuals & Estimates (NASDAQ:LENZ) - TradingView
LENZ Therapeutics, Arrotex Ink Commercialization Deal for VIZZ in Australia and New Zealand - VisionMonday.com
US prices for new drugs fell in 2025 as fewer costly gene therapies were launched - marketscreener.com
LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst - Sahm
LENZ Therapeutics (LENZ) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ By Investing.com - Investing.com South Africa
LENZ Therapeutics signs exclusive VIZZ deal for Australia and New Zealand - grafa.com
LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ - Investing.com Australia
Lenz TherapeuticsArrotex Obtains Exclusive - Moomoo
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand - LENZ Therapeutics
LENZ Therapeutics, Inc. and Arrotex Pharmaceuticals Pty Ltd. Announce Exclusive License and Commercialization Agreement for VIZZ in Australia and New Zealand - marketscreener.com
LENZ Therapeutics Inc (LENZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LENZ Therapeutics, Inc. (LENZ) reports Q1 loss, beats revenue estimates - MSN
LENZ Therapeutics Inc (LENZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LENZ Therapeutics Inc (LENZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LENZ Therapeutics Inc (LENZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LENZ Therapeutics Inc (LENZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LENZ Therapeutics Inc (LENZ) Institutional Confidence - TradingKey
LENZ Therapeutics Inc (LENZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
LENZ Therapeutics Inc (LENZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RA Capital-linked entities receive 22,100 LENZ (LENZ) options via director grant - Stock Titan
LENZ (LENZ) director receives 22,100 stock options at $6.63 strike price - Stock Titan
Director awarded 22,100 LENZ Therapeutics (LENZ) stock options - Stock Titan
Lenz Therapeutics Inc Azioni (LENZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lenz Therapeutics Inc Azioni (LENZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 27 '26 |
Buy |
8.95 |
28,089 |
251,411 |
77,289 |
| Chevallard Daniel R. | Chief Financial Officer |
Mar 27 '26 |
Buy |
8.57 |
7,500 |
64,275 |
12,886 |
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Option Exercise |
2.08 |
10,000 |
20,800 |
14,733 |
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Sale |
26.10 |
10,000 |
261,022 |
4,733 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):